Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025
Provided By GlobeNewswire
Last update: Apr 25, 2025
BDC-3042 was well tolerated up to 10 mg/kg q2w with no dose-limiting toxicities and no drug-related serious adverse events
BDC-3042 showed biological activity, with clear dose-dependent increases in proinflammatory cytokines and chemokines
Read more at globenewswire.comNASDAQ:BOLT (12/5/2025, 5:08:00 PM)
5.42
+0.11 (+2.07%)
Find more stocks in the Stock Screener
